The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

Mar. 15, 2018
Applicant:

Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai, CN;

Inventors:

Wenzhi Tian, Shanghai, CN;

Song Li, Shanghai, CN;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 19/00 (2006.01); C07K 14/705 (2006.01); C07K 16/46 (2006.01); C12P 21/02 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); C07K 14/70596 (2013.01); C07K 19/00 (2013.01); C12P 21/02 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01);
Abstract

Provided is a bi-functional fusion protein as well as its preparation method and use. The bi-functional fusion protein is composed of a monoclonal anti-human CD20 antibody linked to a first extracellular domain of human SIRPα. It is shown in in vitro tests that the bi-functional fusion protein is capable of binding to human CD20 and CD47 simultaneously, thus killing CD20+ tumor cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and is also capable of blocking CD47-SIRPα interaction such that macrophages are activated to attack tumor cells. The bi-functional fusion protein has evident anti-tumor activities.


Find Patent Forward Citations

Loading…